The DIABLO Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat cells, featuring targeted disruption of the DIABLO gene. This product offers a loss-of-function model for dissecting DIABLO-mediated regulation of apoptosis. As a polyclonal population, it captures a range of genetically diverse knockout profiles, making it suitable for pooled functional studies without the selection biases of clonal isolates. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, generating a versatile cellular system for interrogating mitochondrial apoptotic signaling.
The Jurkat cell line is an immortalized human T lymphocyte leukemia model originally derived from the peripheral blood of a 14-year-old male with acute lymphoblastic leukemia. Jurkat cells are widely employed for studying T cell receptor signaling, apoptosis, and immune response mechanisms. Their robust growth and well-characterized signaling properties make them a foundational platform for cancer research and drug discovery. In their native state, Jurkat cells express the pro-apoptotic protein DIABLO, allowing constitutive caspase activation in response to apoptotic stimuli; disruption of DIABLO provides a clear phenotypic contrast for mechanistic studies.
DIABLO is a mitochondrial pro-apoptotic protein that functions as a key regulator of caspase activation. Upon mitochondrial outer membrane permeabilization triggered by pro-apoptotic Bcl-2 family members BAX and BAK, DIABLO is released into the cytosol along with cytochrome c. In the cytosol, DIABLO binds directly to inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 via their BIR domains, thereby neutralizing IAP-mediated caspase suppression, relieving caspase-9 inhibition within the APAF1/cytochrome c apoptosome and allowing executioner caspases-3 and -7 to promote apoptosis. The DIABLO-XIAP interaction is a critical node in the intrinsic apoptosis pathway and IAP signaling, linking mitochondrial damage to cell death commitment.
In the Jurkat T cell leukemia background, DIABLO knockout disrupts normal apoptotic signaling, offering a powerful tool for investigating chemoresistance and cell death defects associated with hematological malignancies. Jurkat cells are inherently sensitive to apoptotic stimuli such as etoposide and staurosporine, and loss of DIABLO may shift the balance toward cell survival by enhancing XIAP-mediated caspase inhibition. This model is therefore relevant for studying how leukemic cells evade apoptosis, and for identifying therapeutic strategies that restore cell death sensitivity. The knockout context also enables exploration of crosstalk between extrinsic death receptors and the mitochondrial pathway, as DIABLO operates at the convergence of these signals.
Typical applications include Western blotting to assess DIABLO expression and caspase processing, flow cytometry using Annexin V/PI staining to quantify apoptosis induction, and caspase activity assays to measure enzymatic function downstream of mitochondrial permeabilization. Co-immunoprecipitation experiments can probe disrupted DIABLO-XIAP interactions, while cytochrome c release assays monitor mitochondrial events. Drug sensitivity screens with chemotherapeutics or IAP antagonists further elucidate the functional role of DIABLO. For additional information, please contact Ascent Research.
